Roles of the tumor suppressor CYLD in progression and personalized medicine of oral cancer
| Project/Area Number |
24792238
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
SHINRIKI Satoru 熊本大学, 医学部附属病院, 特任助教 (00583048)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 国際情報交換 / 口腔扁平上皮癌 / CYLD / TGFβ / EMT / アメリカ |
|---|
| Research Abstract |
We obtained the results as follows;1. Expression of Cylindromatosis (CYLD) was reduced in invasive region in oral squamous cell carcinoma (OSCC) tissues, which was significantly associated with increased Smad3 phosphorylation and worse prognosis. 2. CYLD knockdown inhibited SMURF2-dependent degradation of TGFBR1, leading to promoted TGFbeta signaling activation, acquisition of mesenchymal state and increased migration. 3. CYLD repression led to resistance to cisplatin but increased susceptibility to EGFR tyrosine kinase inhibitor-inducible apoptosis in OSCC cells. 4. Loss of CYLD induced long-term quiescent state in OSCC cells in vitro.
|
Report
(3 results)
Research Products
(10 results)
-
-
-
-
-
-
-
[Presentation] Downregulation of CYLD leads to acquisition of mesenchymal state and increased migration via ligand-independent TGFβR1 activation in human oral squamous cell carcinoma cells2012
Author(s)
Shinriki S, Jono H, Nakamura T, Hayashi M, Yamamoto Y, Ibusuki M, Sueyoshi T, Ota T, Shinohara M, Ando Y
Organizer
103rd AACR Annual Meeting 2012
Place of Presentation
Chicago, Illinois, USA
Related Report
-
-
-
